Contrôle rapide et fiable des préparations de chimiothérapies à base d’anticorps monoclonaux à l’aide de l’automate Multispec®

Gallelli, 1991, Issues and risks associated with handling antineoplastic drugs, J Pharm Pract, 4, 72, 10.1177/089719009100400108 Valanis, 1993, Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel, Am J Hosp Pharm, 50, 455 Power, 1990, Update on safe handling of hazardous drugs: the advice of experts, Am J Hosp Pharm, 47, 1050 DeMeo, 1995, Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials, Int Arch Occup Environ Health, 66, 363, 10.1007/BF00383141 Sessink, 1997, Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures, Arch Environ Health, 52, 240, 10.1080/00039899709602893 Sessink, 1992, Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers, Int Arch Occup Environ Health, 64, 105, 10.1007/BF00381477 Pethran, 2003, Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations, Int Arch Occup Environ Health, 76, 5, 10.1007/s00420-002-0383-8 Ziegler, 2002, Occupational exposure to cytotoxic drugs in two UK oncology wards, Occup Environ Med, 59, 608, 10.1136/oem.59.9.608 Martin, 2004, Maîtrise des erreurs de préparation des médicaments anticancéreux en unité centralisée : de l’épidémiologie à l’assurance qualité, Bull Cancer, 91, 972 Baldo, 2007, A centralized pharmacy unit for cytotoxic drugs in accordance with Italian legislation, J Eval Clin Pract, 13, 265, 10.1111/j.1365-2753.2006.00693.x Cazin, 1999, Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy, Pharm World Sci, 21, 177, 10.1023/A:1008731406552 ASHP guidelines on quality assurance for pharmacy-prepared sterile products. American Society of Health System Pharmacists. Am J Health Syst Pharm 2000;57:1150–69. Favier, 1993, Preparing cytotoxic agents in an isolator, Am J Hosp Pharm, 50, 2335 Tillett, 1999, Barrier isolators as an alternative to a cleanroom, Am J Health Syst Pharm, 56, 1433, 10.1093/ajhp/56.14.1433 Augry, 1996, Évaluation de l’économie réalisée au sein d’une unité centralisée de fabrication des médicaments cytotoxiques destinées à la voie parentérale, J Pharm Clin, 15, 12 Favier, 1996, Economic benefit of a centralized reconstitution unit of cytotoxic drug in isolator, J Oncol Pharm Pract, 2, 182, 10.1177/107815529600200308 Legat, 2003, Impact économique de la préparation centralisée des médicaments anticancéreux, J Pharm Clin, 22, 181 Limat, 2002, Risque iatrogène lié à la prescription des médicaments anticancéreux, Oncologie, 4, 203 Ritter, 1996, Electronic balance as quality assurance for cytotoxic drug admixtures, Am J Health Syst Pharm, 53, 2318, 10.1093/ajhp/53.19.2318 Basuyau, 2000, Comparaison de deux mesures physiques rapides pour le contrôle de la dose des préparations injectables de médicaments anticancéreux avant administration : application au 5-fluorouracile, J Pharm Clin, 19, 5 Havard, 2005, Le contrôle de qualité en unité centralisée de reconstitution des cytotoxiques : mythe ou réalité ?, STP Pharma Prat, 15, 148 Pelus, 1998, Unité de préparation centralisée des cytotoxiques : de la mise en place à l’assurance-qualité, J Pharm Clin, 17, 97 Watt, 2002, New program for quality control of cytotoxics manufactured in centralised unit, J Pharm Clin, 21, 179 Bonan, 2009, The application of hazard analysis and critical control points and risk management in the preparation of anticancer drugs, Int J Qual Health Care, 21, 44, 10.1093/intqhc/mzn052 Escoms, 1996, Errors evolution and analysis in antineoplastic drug preparation during 1 year, Pharm World Sci, 18, 178, 10.1007/BF00820729 Flynn, 1997, Observational study of accuracy in compounding i.v. admixtures at five hospitals, Am J Health Syst Pharm, 54, 904, 10.1093/ajhp/54.8.904 Breton G, Pouliquen AL, François C, Clément I, Daronat M. Méthodes de contrôle des préparations de chimiothérapies : Qu’en est-il ? (résumé). Journées de l’APHIF: Paris; 2008, (abstract 46). Ripoche, 2009, Feasibility study of extemporaneous control of cytotoxic preparations: tests with an innovating spectrometer coupling UV/visible and IR detections, Eur J Hosp Pharm Pract, 15, 28 Therapeutic monoclonal antibodies Report 2008–2023. 2008, Thomson Reuteurs. Pavlou, 2005, The therapeutic antibodies market to 2008, Eur J Pharm Biopharm, 59, 389, 10.1016/j.ejpb.2004.11.007 Chames, 2009, Therapeutic antibodies: successes, limitations and hopes for the future, Br J Pharmacol, 157, 220, 10.1111/j.1476-5381.2009.00190.x Pelton, 2000, Spectroscopic methods for analysis of protein secondary structure, Anal Biochem, 277, 167, 10.1006/abio.1999.4320 Lahlou, 2009, Mechanically-induced aggregation of the monoclonal antibody cetuximab, Ann Pharm Fr, 67, 340, 10.1016/j.pharma.2009.05.008 Kupfer, 2009, Stability of alemtuzumab in infusion-bags, Pharmazie, 64, 622 Bakri, 2006, Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing, Retina, 26, 519, 10.1097/01.iae.0000225354.92444.7a Ornek, 2008, Bevacizumab sterility in multiple doses from a single-use vial, Ann Pharmacother, 42, 1425, 10.1345/aph.1L270 Paul, 2008, Thermal stability of two monoclonal antibodies: cetuximab and bevacizumab, EJOP, 2, 37 Wang, 2007, Antibody structure, instability and formulation, J Pharm Sci, 96, 1, 10.1002/jps.20727 ICH text on validation of analytical procedures: methodology. ICH Harmonised Tripartite Guideline 1996;4:1–8. Barth, 2007, Infrared spectroscopy of proteins, Biochim Biophys Acta, 1767, 1073, 10.1016/j.bbabio.2007.06.004 Levillain, 1986, Spectrophotométrie dérivée : intérêt, limites et applications, Analusis, 14, 1 Joseph-Charles, 1997, Intérêt de la spectrophotométrie dérivée pour l’identification d’une substance, Bull Soc Pharm Bordeaux, 136, 56 Dossier du CNHIM, anticancéreux : utilisation pratique. 6e ed. 2008. Fischer, 2008, Glycation during storage and administration of monoclonal antibody formulations, Eur J Pharm Biopharm, 70, 42, 10.1016/j.ejpb.2008.04.021